Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from Novartis AG

5 Durable Stocks to Strengthen Your Portfolio

Given the current market turmoil caused due to surging inflation and the Fed’s aggressive interest rate hikes to bring prices down, it could be wise to invest in stocks that do not fluctuate significantly in adverse market conditions. The solid stability of Johnson & Johnson (JNJ), Coca-Cola FEMSA (KOF), Marubeni…

StockNews.com

Analysts Remain Bullish Despite Caribou's Allogeneic CAR-T Hit By Durability

Caribou Biosciences Inc (NASDAQ:CRBU) announced the presentation of additional initial clinical data from its ANTLER Phase 1 trial for CB-010 in relapsed or refractory B cell non-Hodgkin lymphoma (r/r B-NHL). Following a single dose at the initial dose level of 40 million CAR-T cells, a 100% complete response (CR) rate (6 of 6…

Benzinga

5 No-Brainer Stocks to Buy if the Market Crashes

Novartis (NVS), Micron Technology (MU), Waste Management (WM), Oracle (ORCL), and Amgen (AMGN) have significant underlying strength of their businesses and therefore would be attractive buy if the stock market crashes.

StockNews.com

From analysis to the latest developments in health,
read the most diverse news in one place.

Worried About a Market Meltdown? Then Buy These 5 Stocks Now

The market’s near-term outlook remains uncertain on concerns over the persistent macroeconomic and geopolitical issues. But we think investors worried about a market meltdown can look to add quality stocks Coca-Cola FEMSA (KOF), CGI (GIB), Novartis (NVS), PLDT (PHI), and Fresenius Medical Care (FMS) to their portfolios because these names…

StockNews.com

New Data Shows Novartis' Kisqali Extends Survival In Postmenopausal Breast Cancer Setting

Novartis AG (NYSE:NVS) has announced updated median overall survival (OS) results for Kisqali (ribociclib) combined with fulvestrant for postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor-2 negative (HR+/HER2-) advanced or metastatic breast cancer. The analysis of patients treated in first-line with Kisqali plus fulvestrant demonstrated a significant OS benefit of nearly…

Benzinga

The Daily Biotech Pulse: Kezar Life's Lead Asset Fails, Brickell Biotech Offloads Late-Stage Asset, Connect Biopharma Ulcerative Colitis Trial Disappoints

Here's a roundup of top developments in the biotech space over the last 24 hours.

Benzinga

Novartis - BeiGene's Tislelizumab Aces Late-Stage Esophageal Cancer Trial

Novartis AG (NYSE:NVS) has announced topline results from an interim analysis of the Phase 3 RATIONALE 306 study of tislelizumab plus chemotherapy in esophageal squamous cell carcinoma (ESCC). Data showed that tislelizumab plus chemotherapy significantly improved overall survival (OS) compared to chemotherapy in patients with previously untreated unresectable, locally advanced, recurrent, or metastatic…

Benzinga

Read news from The Economist, FT, and more,
with one subscription

The Daily Biotech Pulse: Molecular Partners Plunges On Double Bad News, Pfizer/BioNTech Seek Nod For COVID-19 Shot In Kids, Pfizer Invests In Zentalis

Here's a roundup of top developments in the biotech space over the last 24 hours.

Benzinga

Molecular Partners, Novartis Note EUA For COVID-19 Therapy May Need Additional Data

Molecular Partners AG (NASDAQ:MOLN) has provided an update regarding the Emergency Use Application (EUA) for ensovibep, a DARPin antiviral therapeutic candidate to treat COVID-19. The Company says that EUA, in review with the FDA, may require additional clinical data to be authorized. Vas Narasimhan also noted that the current omicron wave of SARS-Cov-2,…

Benzinga

Novartis Posts Higher Q1 Earnings, Sales On Strong Sandoz, Entresto; Backs 2022 Outlook

Novartis AG (NYSE:NVS) has reported a core EPS of $1.46 in Q1 FY22 compared to $1.38 a year ago, beating the consensus of $1.44. Net income reached $2.2 billion, an increase of 8% or 15% at constant currency rates, mainly driven by higher operating income, partly offset by the loss of Roche Holding (OTC:RHHBY) income.…

Benzinga

5 Surging Mega-Cap Stocks to Add to Your Watchlist

The stock market has been experiencing high volatility due to various economic and geopolitical factors. But under these uncertain market conditions investors could add quality mega-cap stocks Novo Nordisk (NVO), Shell (SHEL), Eli Lilly (LLY), Novartis (NVS), and Costco (COST) to their watchlists. Mega-cap stocks are known to endure harsh…

StockNews.com

Novartis' Breast Cancer PI3K Drug, Scores FDA Approval For Ultra-Rare Indication

The FDA has granted accelerated approval to Novartis AG's (NYSE: NVS) Vijoice (alpelisib) for patients 2 years of age and older with severe manifestations of PIK3CA-Related Overgrowth Spectrum (PROS) who require systemic therapy.

Benzinga

Novartis Highlights Four-Year Efficacy, Safety Data On Kesimpta In Multiple Sclerosis

Novartis AG (NYSE:NVS) announced new long-term data from the Phase 3 ASCLEPIOS 1/2 trials and the ALITHIOS open-label extension of Kesimpta (ofatumumab) in multiple sclerosis. The data demonstrated long-term efficacy and safety of Kesimpta with continued reduced risk of disability worsening in relapsing multiple sclerosis following up to four years of treatment. Kesimpta…

Benzinga

Novartis Receives Positive CHMP Opinion For Kymriah In Follicular Lymphoma, Jakavi In GvHD

The European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending approval of Novartis AG's (NYSE: NVS)

Benzinga

Get all your
news in one place.

100’s of premium titles.
One news app.

Benzinga

FDA Approves Novartis' Pluvicto As First Targeted Radioligand Therapy For Prostate Cancer

The FDA approved Novartis AG's (NYSE:NVS) Pluvicto (lutetium Lu 177 vipivotide tetraxetan) to treat patients with a type of advanced prostate cancer that has spread to other parts of the body. Pluvicto is a targeted radioligand therapy for adult patients who have already undergone other anticancer treatments. The company said it had submitted…

Benzinga

Novartis Suspends Some Investment, Business Activities In Russia

Novartis AG (NYSE:NVS) will suspend capital investments, media advertising, and other promotional activities in Russia but remain committed to providing access to its medicine there. "Novartis condemns the war in Ukraine," it said in a statement, adding that "while we remain committed to providing access to our medicine in Russia, we responsibly…

Benzinga

Novartis's Data Reinforces Age-Appropriate Development With Zolgensma Gene Therapy Study

Novartis AG (NYSE:NVS) announced new data from the completed Phase 3 SPR1NT study of Zolgensma (onasemnogene abeparvovec), a one-time treatment for spinal muscular atrophy (SMA). The data demonstrated that children with three copies of the SMN2 backup gene who were treated presymptomatically achieved age-appropriate motor milestones, including standing and walking. In addition, a descriptive posthoc…

Benzinga

NEJM Publication Shows Novartis' Kisqali With Longest Median Overall Survival In Breast Cancer Setting

The New England Journal of Medicine (NEJM) published data from Phase 3 MONALEESA-2 trial of Novartis AG's (NYSE:NVS) Kisqali (ribociclib) plus letrozole demonstrating a statistically significant improvement in overall survival. MONALEESA-2 overall survival data were first presented at the European Society for Medical Oncology Congress in September 2021. The NEJM publication includes additional analyses substantiating the longest median…

Get all your
news in one place.

100’s of premium titles.
One news app.

Benzinga

Voyager Therapeutics Shares Jump On Novartis Option Agreement For Gene Therapy Programs

Novartis AG (NYSE: NVS) has

Benzinga

Molecular Partners, Novartis Submit Emergency Use Authorization Request For Ensovibep For COVID-19

Molecular Partners AG (NASDAQ: MOLN) and its partner Novartis AG (NYSE: NVS), have

Benzinga

Novartis Expects FY22 Sales, Profit Growth; Sandoz Review Continues

Novartis AG (NYSE: NVS) reported a Q4 net income of $16.31 billion, up from $2.1 billion the previous year,

Benzinga

Carlyle, Blackstone Mull $25B Buyout For Novartis' Sandoz Arm: Report

Investor groups Blackstone and Carlyle could join forces on a massive $25 billion bid for Novartis AG's unit (NYSE: NVS) Sandoz,

1 2 3

People

Dipanjan BanchurSince

722 stories

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.